What is pyrazinamide?
Pyrazinamide is an antibacterial prescription medicine approved by the U.S.(FDA) for the treatment of active (TB). (Active TB is also called .)
TB can be an What is an Opportunistic Infection? fact sheet.(OI) of HIV. An OI is an that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about OIs, read the HIVinfo
To learn how HIV and TB are connected, read the HIVinfo HIV and Tuberculosis (TB) fact sheet. The fact sheet includes information on TB treatment in people with HIV/TB .
How is pyrazinamide used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV and the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children include recommendations on the use of pyrazinamide to treat active TB disease in people with HIV.The recommended uses may not always be consistent with FDA-approved uses of pyrazinamide. See the Adult and Pediatric Opportunistic Infection Guidelines for complete information on recommended uses of pyrazinamide in adults and children with HIV. Pyrazinamide may have other recommended uses not listed above.
What should I tell my health care provider before taking pyrazinamide?
Before taking pyrazinamide, tell your health care provider:
- If you are allergic to pyrazinamide or any other medicines.
- About any medical conditions you have or have had, including or kidney problems, or gout.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take tablets.
- If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of taking pyrazinamide during pregnancy. The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV may include other recommendations on the use of pyrazinamide during pregnancy. Please refer to these guidelines for additional information.
- If you are breastfeeding or plan to breastfeed. For women with HIV in the United States, the Guideline does not recommend breastfeeding. Before your baby is born, or if you are already breastfeeding, talk to your health care provider to discuss alternative options for feeding your baby.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Pyrazinamide may affect the way other medicines or products work, and other medicines or products may affect how pyrazinamide works. Ask your health care provider if there are interactions between pyrazinamide and the other medicines you take.
Ask your health care provider about possible side effects from pyrazinamide. Your health care provider will tell you what to do if you have side effects.
How should I take pyrazinamide?
Take pyrazinamide according to your health care provider’s instructions. Your health care provider will tell you how much pyrazinamide to take and when to take it. Before you start pyrazinamide and each time you get a refill, read any printed information that comes with your medicine.
How should pyrazinamide be stored?
- Store pyrazinamide tablets in a well-closed container at room temperature, 59°F to 86°F (15°C to 30°C).
- Keep pyrazinamide in the container that it came in and keep the container tightly closed.
- Do not use pyrazinamide if the original seal over the container opening is broken or missing.
- Throw away pyrazinamide that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep pyrazinamide and all medicines out of reach of children.
Where can I find more information about pyrazinamide?
- Recommendations on the HIV-related use of pyrazinamide, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV and the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children, prepared by the , the , the HIV Medicine Association of the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society.
- This Patient Version drug summary is based on the following FDA label(s): Tablet.
- Pyrazinamide-related research studies, from
Last Reviewed: June 2, 2021